D-dimer, oral anticoagulation, and venous thromboembolism recurrence

Seminars in Vascular Medicine

Volumn 5, Issue 4, 2005, Pages 365-370

  Cosmi, Benilde ^a   Palareti, Gualtiero ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Fibrin degradation products; Recurrence; Thrombosis; Venous thromboembolism; Warfarin

Indexed keywords

ANTIVITAMIN K; D DIMER; WARFARIN;

ANTICOAGULATION; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INTERNATIONAL NORMALIZED RATIO; PREDICTION; RECURRENT DISEASE; REVIEW; THROMBOPHILIA; VEIN OCCLUSION; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; PREDICTIVE VALUE OF TESTS; RECURRENCE; RISK FACTORS; VENOUS THROMBOSIS;

EID: 27244449198     PISSN: 15289648     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-922481     Document Type: Review

References (20)

1. Büller HR, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:401S-428S
2. Hirsh J, Kearon C, Ginsberg J. Duration of anticoagulant therapy after first episode of venous thrombosis in patients with inherited thrombophilia. Arch Intern Med 1997;157: 2174-2177
3. Agnelli G, Prandoni P, Santamaria MG, et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. N Engl J Med 2001;345:165-169
4. Agnelli G, Prandoni P, Becattini C, et al. For the Warfarin Optimal Duration Italian Trial Investigators. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med 2003;139:19-25
5. Pinede L, Ninet J, Duhaut P, et al. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf-vein thrombosis. Circulation 2001;103:2453-2460
6. The DVTENOX study. Markers of hemostatic system activation in acute deep venous thrombosis-evolution during the first days of heparin treatment. Thromb Haemost 1993; 70:909-914
7. Speiser W, Mallek R, Koppensteiner R, et al. D-dimer and TAT measurement in patients with deep venous thrombosis: utility in diagnosis and judgement of anticoagulation treatment effectiveness. Thromb Haemost 1990;64:196-201
8. Kakkar VV, Hoppenstead D, Fareed J, et al. Randomized trial of different regimens of heparin and in vivo thrombin generation in acute deep vein thrombosis. Blood 2002;99: 1965-1970
9. Estivals M, Pelzer H, Sie P, et al. Prothrombin fragment 1 + 2, thrombin-antithrombin III complexes and D-dimers in acute deep vein thrombosis: effects of heparin treatment. Br J Haematol 1991;78:421-424
10. Kévorkian JP, Halimi C, Segrestaa JM, Drouet L, Soria C. Monitoring of patients with deep-vein thrombosis during and after anticoagulation with D-dimer. Lancet 1998;351:571-572
11. Fattorini A, Crippa L, Viganò D'Angelo S, Pattarini E, D'Angelo A. Risk of deep vein thrombosis recurrence: high negative predictive value of D-dimer performed during oral anticoagulation. Thromb Haemost 2002;88:162-163
12. Palareti G, Legnani C, Cosmi B, Guazzaloca G, Pancani C, Coccheri S. Risk of venous thromboembolic recurrence: high negative predictive value of D-dimer performed after oral anticoagulation is stopped. Thromb Haemost 2002;87: 7-12
13. Kuruvilla J, Wells P, Morrow B, MacKinnon K, Keeney M, Kovacs MJ. Prospective assessment of the natural history of positive D-dimer results in persons with acute venous thromboembolism (DVT or PE). Thromb Haemost 2003; 89:284-287
14. Eichinger S, Minar E, Bialonczyk C, et al. D-dimer levels and risk of recurrent venous thromboembolism. JAMA 2003;290: 1071-1074
15. Palareti G, Legnani C, Cosmi B, et al. Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia. Circulation 2003;108:313-318
16. Palareti G, Legnani C, Cosmi B, Guazzaloca G, Cini M, Mattarozzi S. Poor anticoagulation quality in the first three months after unprovoked venous thromboembolism is a risk factor for long term recurrence. J Thromb Haemost 2005;3: 955-961
17. Piovella F, Crippa L, Barone M, et al. Normalization rates of compression ultrasonography in patients with a first episode of deep vein thrombosis of the lower limbs: association with DVT recurrence and new thrombosis. Haematologica 2002; 87:515-522
18. Prandoni P, Lensing AWA, Prins MH, et al. Residual vein thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med 2002;137:955-960
19. Cosmi B, Legnani C, Cini M, Guazzaloca G, Palareti G. The effect of D-dimer and residual venous obstruction on the risk of recurrence after anticoagulation withdrawal for a first idiopathic deep vein thrombosis. Thromb Haemost 2005;90: In press
20. Palareti G, Tosetto A, Cosmi B, et al. The D-dimer test to establish the duration of anticoagulation after a first unprovoked episode of venous thromboembolism (VTE); the prospective randomized "Prolong" Study. Presented at the XXth Congress of the International Society on Thrombosis and Haemostasis (ISTH); Sydney, Australia; August 6-12, 2005